Results 21 to 30 of about 21,874 (160)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer

European Journal of Breast Health, 2015
Lapatinib is an effective drug in HER2-positive breast cancer. We present a case with successful treatment of lapatinib in brain metastasis of HER2+ breast cancer. Forty-eight years old woman was admitted our clinic with early breast cancer.
Bülent Karagöz, Alpaslan Özgün, Levent Emirzeoğlu, Tolga Tunçel, Serkan Çelik, Oğuz Bilgi, Kemal Kara   +6 more
doaj   +1 more source

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Cancer Medicine, 2020
Lapatinib is widely used in the later lines treatment of HER2 positive metastatic breast cancer (MBC). EGF104900 study suggested that among patients who experienced progression on prior trastuzumab‐containing regimens, lapatinib plus trastuzumab had ...
Yizhao Xie, Rui Ge, Die Sang, Ting Luo, Wei Li, Xuening Ji, Peng Yuan, Biyun Wang   +7 more
doaj   +1 more source

Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines

Biomedicines, 2019
Lapatinib is an orally administered, dual ErbB1/ErbB2 tyrosine kinase inhibitor (TKI). It is effective in ErbB2 + ve breast cancer treatment. However, lapatinib is associated with diarrhoea with an incidence of 47−75%.
Wan Nor I′zzah Wan Mohamad Zain, Joanne Bowen, Emma Bateman, Dorothy Keefe   +3 more
doaj   +1 more source

Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis

Frontiers in Pharmacology, 2020
Epilepsy is a complex neurological disorder characterized by recurrent and unprovoked seizures. Neuronal death process is implicated in the development of repetitive epileptic seizures.
Ji-Ning Jia, Ji-Ning Jia, Ji-Ning Jia, Ji-Ning Jia, Xi-Xi Yin, Qin Li, Qin Li, Qin Li, Qin Li, Qi-Wen Guan, Qi-Wen Guan, Qi-Wen Guan, Qi-Wen Guan, Nan Yang, Nan Yang, Nan Yang, Nan Yang, Kang-Ni Chen, Kang-Ni Chen, Kang-Ni Chen, Kang-Ni Chen, Hong-Hao Zhou, Hong-Hao Zhou, Hong-Hao Zhou, Hong-Hao Zhou, Xiao-Yuan Mao, Xiao-Yuan Mao, Xiao-Yuan Mao, Xiao-Yuan Mao   +28 more
doaj   +1 more source

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis

Systematic Reviews, 2022
Introduction Trastuzumab, as the gold standard for HER2-positive BC treatment, was the first-line HER2 targeted drug. However, some studies reported patients benefited more from lapatinib and lapatinib plus trastuzumab therapy than standard trastuzumab ...
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
doaj   +1 more source

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

Molecular Cancer, 2012
Background Lapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer.
O’Neill Fiona, Madden Stephen F, Aherne Sinead T, Clynes Martin, Crown John, Doolan Padraig, O’Connor Robert   +6 more
doaj   +1 more source

The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. [PDF]

PLoS ONE, 2015
Idiosyncratic lapatinib-induced liver injury has been reported to be associated with human leukocyte antigen (HLA)-DRB1*07:01. In order to investigate its mechanism, interaction of lapatinib with HLA-DRB1*07:01 and its ligand peptide derived from tetanus
Makoto Hirasawa, Katsunobu Hagihara, Noriko Okudaira, Takashi Izumi   +3 more
doaj   +1 more source

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

PLoS ONE, 2015
We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors ...
James E Korkola, Eric A Collisson, Laura Heiser, Chris Oates, Nora Bayani, Sleiman Itani, Amanda Esch, Wallace Thompson, Obi L Griffith, Nicholas J Wang, Wen-Lin Kuo, Brian Cooper, Jessica Billig, Safiyyah Ziyad, Jenny L Hung, Lakshmi Jakkula, Heidi Feiler, Yiling Lu, Gordon B Mills, Paul T Spellman, Claire Tomlin, Sach Mukherjee, Joe W Gray   +22 more
doaj   +1 more source

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China

Technology in Cancer Research & Treatment, 2021
Background: The aim of this study was to evaluate the effectiveness of lapatinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Xinzhao Wang MD, Lin Wang MD, Qian Yu PhD, Zhaoyun Liu MD, Chao Li MD, Fukai Wang MD, Zhiyong Yu MD, PhD   +6 more
doaj   +1 more source

Single‐Cell Transcriptomic Analysis of Tumor Heterogeneity and the Microenvironment in Pseudomyxoma Peritonei

Advanced Science, EarlyView.
This study presents a single‐cell atlas of pseudomyxoma peritonei spanning primary and paired metastatic lesions. Distinct epithelial substates, stromal remodeling, immune exclusion, lipid metabolic reprogramming, and a candidate angiogenic network were identified in metastatic lesions.
Xi Li, Lei Wang, Lei Ai, Zimeng Li, Zhaochangci Chen, Yuchen Luo, Tianran Zhang, Mengjia Liao, Songhao Wang, Jiajia Cui, Ke Liu, Chengxian Guo, Guodong Liu, Jiye Yin, Wei Wu   +14 more
wiley   +1 more source